Beyond Chemotherapy and Immunotherapy in Thoracic Malignancies: Overcoming Resistance by Tackling New Molecular Pathways

11k
Total downloads
40k
Total views and downloads

Articles

EDITORIAL

Published on 16 Sep 2022

Editorial: Beyond chemotherapy and immunotherapy in thoracic malignancies: Overcoming resistance by tackling new molecular pathways

Giannis Mountzios
Giuseppe Luigi Banna
Christian Rolfo

doi 10.3389/fonc.2022.997404

1,570 views
1 citation

REVIEW

Published on 20 Apr 2022

The Landscape of Immunotherapy Resistance in NSCLC

Daniele Frisone
Alex Friedlaender
Alfredo Addeo
Petros Tsantoulis

The Landscape of Immunotherapy Resistance in NSCLC

doi 10.3389/fonc.2022.817548

13,364 views
40 citations

ORIGINAL RESEARCH

Published on 08 Mar 2022

The Effect of Extracellular Superoxide Dismutase (SOD3) Gene in Lung Cancer

Yundi Zhang
Xuan Lu
Yueyang Zhang
Dongbo Zhao
Haoming Gong
Yuxin Du
Hua Sun

The Effect of Extracellular Superoxide Dismutase (SOD3) Gene in Lung Cancer

doi 10.3389/fonc.2022.722646

2,120 views
7 citations

REVIEW

Published on 09 Feb 2022

Research Progress of Anti-PD-1/PD-L1 Immunotherapy Related Mechanisms and Predictive Biomarkers in NSCLC

Fenglong Bie
He Tian
Nan Sun
Ruochuan Zang
Moyan Zhang
Peng Song
Lei Liu
Yue Peng
Guangyu Bai
1 more
Shugeng Gao

Research Progress of Anti-PD-1/PD-L1 Immunotherapy Related Mechanisms and Predictive Biomarkers in NSCLC

doi 10.3389/fonc.2022.769124

4,435 views
26 citations

ORIGINAL RESEARCH

Published on 31 Jan 2022

Acute Phase Proteins as Early Predictors for Immunotherapy Response in Advanced NSCLC: An Explorative Study

Marc A. Schneider
Adriana Rozy
Sabine Wrenger
Petros Christopoulos
Thomas Muley
Michael Thomas
Michael Meister
Tobias Welte
Joanna Chorostowska-Wynimko
Sabina Janciauskiene

Acute Phase Proteins as Early Predictors for Immunotherapy Response in Advanced NSCLC: An Explorative Study

doi 10.3389/fonc.2022.772076

1,907 views
11 citations

ORIGINAL RESEARCH

Published on 23 Dec 2021

A Retrospective Analysis of the Effect of Anlotinib in Patients With Lung Cancer With or Without Previous Antiangiogenic Therapy

Jiaojiao Suo
Yu Sun
Yan Fu
Weigang Xiu
Xuanwei Zhang
Yan Wang
Jiang Zhu

A Retrospective Analysis of the Effect of Anlotinib in Patients With Lung Cancer With or Without Previous Antiangiogenic Therapy

doi 10.3389/fonc.2021.788837

1,298 views
1 citation

ORIGINAL RESEARCH

Published on 20 Oct 2021

SPTBN2, a New Biomarker of Lung Adenocarcinoma

Chunli Wu
Bo Dong
Lan Huang
Yafei Liu
Guanchao Ye
Shihao Li
Yu Qi

SPTBN2, a New Biomarker of Lung Adenocarcinoma

doi 10.3389/fonc.2021.754290

3,253 views
12 citations

CLINICAL TRIAL

Published on 08 Sep 2021

A Phase I Trial of Dasatinib and Osimertinib in TKI Naïve Patients With Advanced EGFR-Mutant Non-Small-Cell Lung Cancer

Chul Kim
Stephen V. Liu
Jennifer Crawford
Tisdrey Torres
Vincent Chen
Jillian Thompson
Ming Tan
Giuseppe Esposito
Deepa S. Subramaniam
Giuseppe Giaccone

A Phase I Trial of Dasatinib and Osimertinib in TKI Naïve Patients With Advanced EGFR-Mutant Non-Small-Cell Lung Cancer

doi 10.3389/fonc.2021.728155

3,949 views
13 citations

ORIGINAL RESEARCH

Published on 06 Sep 2021

DNA Methylation Regulator-Meditated Modification Patterns Define the Distinct Tumor Microenvironment in Lung Adenocarcinoma

Didi Yuan
Zehong Wei
Yicheng Wang
Fang Cheng
Yujie Zeng
Li Yang
Shangyu Zhang
Jianbo Li
Renkuan Tang

DNA Methylation Regulator-Meditated Modification Patterns Define the Distinct Tumor Microenvironment in Lung Adenocarcinoma

doi 10.3389/fonc.2021.734873

1,866 views
5 citations

Share on

Frontiers in Oncology

Frontiers in Oncology

Thoracic Oncology

Impact

40kTopic views
28kArticle views
11kArticle downloads